Machine learning-based radiomics in neurodegenerative and cerebrovascular disease

Abstract

Cognitive impairments, which can be caused by neurodegenerative and cerebrovascular disease, represent a growing global health crisis with far-reaching implications for individuals, families, healthcare systems, and economies worldwide. Notably, neurodegenerative-induced cognitive impairment often presents a different pattern and severity compared to cerebrovascular-induced cognitive impairment. With the development of computational technology, machine learning techniques have developed rapidly, which offers a powerful tool in radiomic analysis, allowing a more comprehensive model that can handle high-dimensional, multivariate data compared to the traditional approach. Such models allow the prediction of the disease development, as well as accurately classify disease from overlapping symptoms, therefore facilitating clinical decision making. This review will focus on the application of machine learning-based radiomics on cognitive impairment caused by neurogenerative and cerebrovascular disease. Within the neurodegenerative category, this review primarily focuses on Alzheimer’s disease, while also covering other conditions such as Parkinson’s disease, Lewy body dementia, and Huntington’s disease. In the cerebrovascular category, we concentrate on poststroke cognitive impairment, including ischemic and hemorrhagic stroke, with additional attention given to small vessel disease and moyamoya disease. We also review the specific challenges and limitations when applying machine learning radiomics, and provide our suggestion to overcome those limitations towards the end, and discuss what could be done for future clinical use.

Keywords

machine learning / neuroimaging / poststroke cognitive impairment / radiomics / stroke

References

[1] Rost NS, Brodtmann A, Pase MP, et al. Post-stroke cognitive impairment and dementia. Circ Res. 2022; 130(8): 1252-1271.

[2] Tian Z, Ji X, Liu J. Neuroinflammation in vascular cognitive impairment and dementia: current evidence, advances, and prospects. Int J Mol Sci. 2022; 23(11): 6224.

[3] Zhao L, Biesbroek JM, Shi L, et al. Strategic infarct location for post-stroke cognitive impairment: a multivariate lesion-symptom mapping study. J Cereb Blood Flow Metab. 2018; 38(8): 1299-1311.

[4] Hu HY, Ou YN, Shen XN, et al. White matter hyperintensities and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 36 prospective studies. Neurosci Biobehav Rev. 2021; 120: 16-27.

[5] Nandi A, Counts N, Chen S, et al. Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: a value of statistical life approach. EClinicalMedicine. 2022; 51: 101580.

[6] Chowdhary N, Barbui C, Anstey KJ, et al. Reducing the risk of cognitive decline and dementia: WHO recommendations. Front Neurol. 2022; 12: 765584.

[7] Strilciuc S, Grad DA, Radu C, et al. The economic burden of stroke: a systematic review of cost of illness studies. J Med Life. 2021; 14(5): 606-619.

[8] Zhang J, Song S, Zhao Y, Ma G, Jin Y, Zheng ZJ. Economic burden of comorbid chronic conditions among survivors of stroke in China: 10-year longitudinal study. BMC Health Serv Res. 2021; 21(1): 978.

[9] Grueso S, Viejo-Sobera R. Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review. Alzheimers Res Ther. 2021; 13(1): 162.

[10] Mirzaei G, Adeli H. Machine learning techniques for diagnosis of Alzheimer disease, mild cognitive disorder, and other types of dementia. Biomed Signal Process Control. 2022; 72: 103293.

[11] Graham SA, Lee EE, Jeste DV, et al. Artificial intelligence approaches to predicting and detecting cognitive decline in older adults: a conceptual review. Psychiatry Res. 2020; 284: 112732.

[12] Revathi A, Kaladevi R, Ramana K, Jhaveri RH, Rudra Kumar M, Prasanna Kumar MS. Early detection of cognitive decline using machine learning algorithm and cognitive ability test. Secur Commun Netw. 2022; 2022(1): 4190023.

[13] Khan P, Kader F, Islam SMR, et al. Machine learning and deep learning approaches for brain disease diagnosis: principles and recent advances. IEEE Access. 2021; 9: 37622-37655.

[14] Myszczynska MA, Ojamies PN, Lacoste AMB, et al. Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. Nat Rev Neurol. 2020; 16(8): 440-456.

[15] Vázquez-Marrufo M, Sarrias-Arrabal E, García-Torres M, Martín-Clemente R, Izquierdo G. A systematic review of the application of machine-learning algorithms in multiple sclerosis. Neurol Engl Ed. 2023; 38(8): 577-590.

[16] Evaluation of Cognitive Impairment and Dementia—UpToDate. Accessed August 31, 2024. https://www.uptodate.com/contents/evaluation-of-cognitive-impairment-and-dementia

[17] Berg D, Borghammer P, Fereshtehnejad SM, et al. Prodromal Parkinson disease subtypes—key to understanding heterogeneity. Nat Rev Neurol. 2021; 17(6): 349-361.

[18] Sengoku R. Aging and Alzheimer’s disease pathology. Neuropathology. 2020; 40(1): 22-29.

[19] Bakels HS, Roos RAC, van Roon-Mom WMC, de Bot ST. Juvenile-onset Huntington disease pathophysiology and neurodevelopment: a review. Mov Disord. 2022; 37(1): 16-24.

[20] Matar E, Ehgoetz Martens KA, Halliday GM, Lewis SJG. Clinical features of Lewy body dementia: insights into diagnosis and pathophysiology. J Neurol. 2020; 267(2): 380-389.

[21] Glasmacher SA, Thomas HS, Stirland L, et al. Incidental findings identified on head MRI for investigation of cognitive impairment: a retrospective review. Dement Geriatr Cogn Disord. 2019; 48(3-4): 123-130.

[22] Vannini P, Hanseeuw BJ, Gatchel JR, et al. Trajectory of unawareness of memory decline in individuals with autosomal dominant Alzheimer disease. JAMA Netw Open. 2020; 3(12): e2027472.

[23] Eikelboom WS, van den Berg E, Singleton EH, et al. Neuropsychiatric and cognitive symptoms across the Alzheimer disease clinical spectrum. Neurology. 2021; 97(13): e1276-e1287.

[24] Oros MM. Cognitions and chronic cerebrovascular disease (small vessel disease). Int Neurol J. 2021; 17(5): 76-81.

[25] Lin Z, Sur S, Liu P, et al. Blood–brain barrier breakdown in relationship to Alzheimer and vascular disease. Ann Neurol. 2021; 90(2): 227-238.

[26] Korte N, Nortley R, Attwell D. Cerebral blood flow decrease as an early pathological mechanism in Alzheimer’s disease. Acta Neuropathol. 2020; 140(6): 793-810.

[27] Geng J, Gao F, Ramirez J, et al. Secondary thalamic atrophy related to brain infarction may contribute to post-stroke cognitive impairment. J Stroke Cerebrovasc Dis. 2023; 32(2): 106895.

[28] Wang H, Yu M, Ren J, et al. Neuroanatomical correlates of cognitive impairment following basal ganglia-thalamic post-hemorrhagic stroke: uncovering network-wide alterations in hemispheric gray matter asymmetry. Brain Res. 2023; 1820: 148559.

[29] Khikmatullaeva K, Khaydarov NK, Abdullaeva MB, Aktamova MU. Cognitive disorders in stroke. Int J Health Med Sci. 2021; 4(2): 202-207.

[30] Huang YY, Chen SD, Leng XY, et al. Post-stroke cognitive impairment: epidemiology, risk factors, and management. J Alzheimers Dis. 2022; 86(3): 983-999.

[31] Hamilton OKL, Backhouse EV, Janssen E, et al. Cognitive impairment in sporadic cerebral small vessel disease: a systematic review and meta-analysis. Alzheimers Dement. 2021; 17(4): 665-685.

[32] Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016; 278(2): 563-577.

[33] Chen Q, Xia T, Zhang M, Xia N, Liu J, Yang Y. Radiomics in stroke neuroimaging: techniques, applications, and challenges. Aging Dis. 2021; 12(1): 143-154.

[34] Górriz JM, Jiménez-Mesa C, Segovia F, Ramírez J, Group S, Suckling J. A connection between pattern classification by machine learning and statistical inference with the general linear model. IEEE J Biomed Health Inform. 2022; 26(11): 5332-5343.

[35] Maulud D, Abdulazeez AM. A review on linear regression comprehensive in machine learning. J Appl Sci Technol Trends. 2020; 1(2): 140-147.

[36] Schulz MA, Yeo BTT, Vogelstein JT, et al. Different scaling of linear models and deep learning in UKBiobank brain images versus machine-learning datasets. Nat Commun. 2020; 11(1): 4238.

[37] Dumitrescu E, Hué S, Hurlin C, Tokpavi S. Machine learning for credit scoring: improving logistic regression with non-linear decision-tree effects. Eur J Oper Res. 2022; 297(3): 1178-1192.

[38] Hale JM, Schneider DC, Mehta NK, Myrskylä M. Cognitive impairment in the U.S.: lifetime risk, age at onset, and years impaired. SSM—Popul Health. 2020; 11: 100577.

[39] Luchetti M, Terracciano A, Aschwanden D, Lee JH, Stephan Y, Sutin AR. Loneliness is associated with risk of cognitive impairment in the survey of health, ageing and retirement in Europe. Int J Geriatr Psychiatry. 2020; 35(7): 794-801.

[40] Malekloo A, Ozer E, AlHamaydeh M, Girolami M. Machine learning and structural health monitoring overview with emerging technology and high-dimensional data source highlights. Struct Health Monit. 2022; 21(4): 1906-1955.

[41] Manzhos S, Ihara M. Advanced machine learning methods for learning from sparse data in high-dimensional spaces: a perspective on uses in the upstream of development of novel energy technologies. Physchem. 2022; 2(2): 72-95.

[42] Spooner A, Chen E, Sowmya A, et al. A comparison of machine learning methods for survival analysis of high-dimensional clinical data for dementia prediction. Sci Rep. 2020; 10(1): 20410.

[43] Bommert A, Sun X, Bischl B, Rahnenführer J, Lang M. Benchmark for filter methods for feature selection in high-dimensional classification data. Comput Stat Data Anal. 2020; 143: 106839.

[44] Santos CFGD, Papa JP. Avoiding overfitting: a survey on regularization methods for convolutional neural networks. ACM Comput Surv. 2022; 54(10s):213:1-213:25.

[45] Kernbach JM, Staartjes VE. Foundations of machine learning-based clinical prediction modeling: part II—generalization and overfitting. In: Staartjes VE, Regli L, Serra C, eds. Machine Learning in Clinical Neuroscience. Springer International Publishing; 2022: 15-21.

[46] Rice L, Wong E, Kolter Z. Overfitting in adversarially robust deep learning. In: Proceedings of the 37th International Conference on Machine Learning. PMLR; 2020: 8093-8104.

[47] Demir F, Akbulut Y. A new deep technique using R-CNN model and L1NSR feature selection for brain MRI classification. Biomed Signal Process Control. 2022; 75: 103625.

[48] Toğaçar M, Cömert Z, Ergen B. Classification of brain MRI using hyper column technique with convolutional neural network and feature selection method. Expert Syst Appl. 2020; 149: 113274.

[49] Sharif MI, Li JP, Khan MA, Saleem MA. Active deep neural network features selection for segmentation and recognition of brain tumors using MRI images. Pattern Recognit Lett. 2020; 129: 181-189.

[50] Krishnan R, Rajpurkar P, Topol EJ. Self-supervised learning in medicine and healthcare. Nat Biomed Eng. 2022; 6(12): 1346-1352.

[51] Glielmo A, Husic BE, Rodriguez A, Clementi C, Noé F, Laio A. Unsupervised learning methods for molecular simulation data. Chem Rev. 2021; 121(16): 9722-9758.

[52] Guo T, Yu K, Aloqaily M, Wan S. Constructing a prior-dependent graph for data clustering and dimension reduction in the edge of AIoT. Future Gener Comput Syst. 2022; 128: 381-394.

[53] Avanzo M, Stancanello J, El Naqa I. Beyond imaging: the promise of radiomics. Phys Med. 2017; 38: 122-139.

[54] Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Neurosci. 2020; 23(10): 1183-1193.

[55] Roda AR, Serra-Mir G, Montoliu-Gaya L, Tiessler L, Villegas S. Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease. Neural Regen Res. 2022; 17(8): 1666.

[56] Pereira JB, Janelidze S, Ossenkoppele R, et al. Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease. Brain. 2021; 144(1): 310-324.

[57] Katako A, Shelton P, Goertzen AL, et al. Machine learning identified an Alzheimer’s disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson’s disease dementia. Sci Rep. 2018; 8(1): 13236.

[58] Ma D, Yee E, Stocks JK, et al. Blinded clinical evaluation for dementia of Alzheimer’s type classification using FDG-PET: a comparison between feature-engineered and non-feature-engineered machine learning methods. J Alzheimers Dis. 2021; 80(2): 715-726.

[59] Kim S, Lee P, Oh KT, et al. Deep learning-based amyloid PET positivity classification model in the Alzheimer’s disease continuum by using 2-[18F]FDG PET. EJNMMI Res. 2021; 11(1): 56.

[60] Shen XX, Zhang HD, Fu HG, et al. Association of cognitive function and hypoperfusion in Moyamoya disease patients without stroke. J Cereb Blood Flow Metab. 2023; 43(4): 542-551.

[61] Beheshti I, Geddert N, Perron J, Gupta V, Albensi BC, Ko JH. Monitoring Alzheimer’s disease progression in mild cognitive impairment stage using machine learning-based FDG-PET classification methods. J Alzheimers Dis. 2022; 89(4): 1493-1502.

[62] Tufail AB, Ma YK, Kaabar MKA, Rehman AU, Khan R, Cheikhrouhou O. Classification of initial stages of Alzheimer’s disease through pet neuroimaging modality and deep learning: quantifying the impact of image filtering approaches. Mathematics. 2021; 9(23): 3101.

[63] Yang BH, Chen JC, Chou WH, et al. Classification of Alzheimer’s Disease from 18F-FDG and 11C-PiB PET imaging biomarkers using support vector machine. J Med Biol Eng. 2020; 40(4): 545-554.

[64] Borji A, Seifi A, Hejazi TH. An efficient method for detection of Alzheimer’s disease using high-dimensional PET scan images. Intell Decis Technol. 2023; 17(3): 729-749.

[65] Nancy Noella RS, Priyadarshini J. Machine learning algorithms for the diagnosis of Alzheimer and Parkinson disease. J Med Eng Technol. 2023; 47(1): 35-43.

[66] Zhou P, Zeng R, Yu L, et al. Deep-learning radiomics for discrimination conversion of Alzheimer’s disease in patients with mild cognitive impairment: a study based on 18F-FDG pet imaging. Front Aging Neurosci. 2021; 13.

[67] Segovia F, Ramírez J, Castillo-Barnes D, et al. Multivariate analysis of dual-point amyloid PET intended to assist the diagnosis of Alzheimer’s disease. Neurocomputing. 2020; 417: 1-9.

[68] Nai YH, Tay YH, Tanaka T, et al. Comparison of three automated approaches for classification of amyloid-PET images. Neuroinformatics. 2022; 20(4): 1065-1075.

[69] Park SW, Yeo NY, Kim Y, Byeon G, Jang JW. Deep learning application for the classification of Alzheimer’s disease using 18F-flortaucipir (AV-1451) tau positron emission tomography. Sci Rep. 2023; 13(1).

[70] Almgren H, Camacho M, Hanganu A, et al. Machine learning-based prediction of longitudinal cognitive decline in early Parkinson’s disease using multimodal features. Sci Rep. 2023; 13(1): 13193.

[71] Gebre RK, Rial AM, Raghavan S, et al. Advancing Tau PET quantification in Alzheimer disease with machine learning: introducing THETA, a novel tau summary measure. J Nucl Med. 2024.

[72] Battineni G, Chintalapudi N, Amenta F, Traini E. A comprehensive machine-learning model applied to magnetic resonance imaging (MRI) to predict Alzheimer’s disease (AD) in older subjects. J Clin Med. 2020; 9(7): 2146.

[73] Azam Zia M, Saeed Z, Asghar N, Majeed B, Hashim M, Identification of Alzheimer disease by using hybrid deep models. In: Xu J, Altiparmak F, Hassan MHA, García Márquez FP, Hajiyev A, eds. Proceedings of the Sixteenth International Conference on Management Science and Engineering Management. Vol 1. Springer International Publishing; 2022: 465-475.

[74] Fan Z, Xu F, Qi X, Li C, Yao L. Classification of Alzheimer’s disease based on brain MRI and machine learning. Neural Comput Appl. 2020; 32(7): 1927-1936.

[75] Duc NT, Ryu S, Qureshi MNI, Choi M, Lee KH, Lee B. 3D-deep learning based automatic diagnosis of Alzheimer’s disease with joint MMSE prediction using resting-state fMRI. Neuroinformatics. 2020; 18(1): 71-86.

[76] Jiang H, Cao P, Xu M, Yang J, Zaiane O. Hi-GCN: a hierarchical graph convolution network for graph embedding learning of brain network and brain disorders prediction. Comput Biol Med. 2020; 127: 104096.

[77] Ju R, Hu C, Zhou P, Li Q. Early diagnosis of Alzheimer’s disease based on resting-state brain networks and deep learning. IEEE/ACM Trans Comput Biol Bioinform. 2019; 16(1): 244-257.

[78] Mahjabeen A, Mia MR, Shariful FNU, Faruqui N, Mahmud I. Early prediction and analysis of DTI and MRI-based Alzheimer’s disease through machine learning techniques. In: Kaiser MS, Waheed S, Bandyopadhyay A, Mahmud M, Ray K, eds. Proceedings of the Fourth International Conference on Trends in Computational and Cognitive Engineering. Springer Nature; 2023: 3-13.

[79] Li Y, Chen G, Wang G, et al. Dominating Alzheimer’s disease diagnosis with deep learning on sMRI and DTI-MD. Front Neurol. 2024; 15: 1444795.

[80] Bron EE, Klein S, Papma JM, et al. Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer’s disease. NeuroImage Clin. 2021; 31: 102712.

[81] EL-Geneedy M, Moustafa HED, Khalifa F, Khater H, AbdElhalim E. An MRI-based deep learning approach for accurate detection of Alzheimer’s disease. Alex Eng J. 2023; 63: 211-221.

[82] Li H, Song Q, Zhang R, Zhou Y, Kong Y. Enhanced temporal coupling between thalamus and dorsolateral prefrontal cortex mediates chronic low back pain and depression. Neural Plast. 2021; 2021(1): 7498714.

[83] Ramzan F, Khan MUG, Rehmat A, et al. A deep learning approach for automated diagnosis and multi-class classification of Alzheimer’s disease stages using resting-state fMRI and residual neural networks. J Med Syst. 2019; 44(2): 37.

[84] Alorf A, Khan MUG. Multi-label classification of Alzheimer’s disease stages from resting-state fMRI-based correlation connectivity data and deep learning. Comput Biol Med. 2022; 151: 106240.

[85] Zhu Q, Wang Y, Zhuo C, et al. Classification of Alzheimer’s disease based on abnormal hippocampal functional connectivity and machine learning. Front Aging Neurosci. 2022; 14: 754334.

[86] Wang B. Enhanced brain efficiency network by integrating the new causality with fMRI and its application for Alzheimer’s disease study. Biomed Signal Process Control. 2023; 86: 105364.

[87] Zhao Y, Guo Q, Zhang Y, et al. Application of deep learning for prediction of Alzheimer’s disease in PET/MR imaging. Bioengineering. 2023; 10(10): 1120.

[88] Subramanyam Rallabandi VP, Seetharaman K. Deep learning-based classification of healthy aging controls, mild cognitive impairment and Alzheimer’s disease using fusion of MRI-PET imaging. Biomed Signal Process Control. 2023; 80: 104312.

[89] Shaffi N, Hajamohideen F, Abdesselam A, Mahmud M, Subramanian K. Ensemble classifiers for a 4-way classification of Alzheimer’s disease. In: Mahmud M, Ieracitano C, Kaiser MS, Mammone N, Morabito FC, eds. Applied Intelligence and Informatics. Springer Nature Switzerland; 2022: 219-230.

[90] Chatterjee S, Byun YC. Voting ensemble approach for enhancing Alzheimer’s disease classification. Sensors. 2022; 22(19): 7661.

[91] Javeed A, Dallora AL, Berglund JS, Anderberg P. An intelligent learning system for unbiased prediction of dementia based on Autoencoder and Adaboost ensemble learning. Life. 2022; 12(7): 1097.

[92] Llamas-Rodríguez J, Oltmer J, Greve DN, et al. Entorhinal subfield vulnerability to neurofibrillary tangles in aging and the preclinical stage of Alzheimer’s disease. J Alzheimers Dis. 2022; 87(3): 1379-1399.

[93] Atalar A, Adar N, Okyay S. A Novel Fusion Method of 3D MRI and Test Results Through Deep Learning for the Early Detection of Alzheimer’s Disease. August 20, 2024. doi:10.1101/2024.08.15.24312032

[94] Singh A, Shi W, Wang MD. Multi-modal deep feature integration for Alzheimer’s disease staging. In: 2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). 2023: 1-6.

[95] Bapat R, Ma D, Duong TQ. Predicting four-year’s Alzheimer’s disease onset using longitudinal neurocognitive tests and MRI Data Using Explainable Deep Convolutional Neural Networks. J Alzheimers Dis. 2024; 97(1): 459-469.

[96] Rudroff T, Rainio O, Klén R. AI for the prediction of early stages of Alzheimer’s disease from neuroimaging biomarkers—a narrative review of a growing field. Neurol Sci. 2024.

[97] An Q, Zhang M, Hu X, Su C, Wang F, Zhu Y. Integrative Analyses of Neuroimaging, Clinical, and Multi-Omics Data Identified Meaningful Alzheimer’s Disease Progression Subtypes. November 10, 2022.

[98] Kumar S, Oh I, Schindler S, Lai AM, Payne PRO, Gupta A. Machine learning for modeling the progression of Alzheimer disease dementia using clinical data: a systematic literature review. JAMIA Open. 2021; 4(3): ooab052.

[99] Shmulev Y, Belyaev M. Predicting conversion of mild cognitive impairments to Alzheimer’s disease and exploring impact of neuroimaging. In: Stoyanov D, Taylor Z, Ferrante E, eds. Graphs in Biomedical Image Analysis and Integrating Medical Imaging and Non-Imaging Modalities. Springer International Publishing; 2018: 83-91.

[100] Karlsson L, Vogel J, Arvidsson I, et al. A Machine Learning-Based Prediction of Tau Load and Distribution in Alzheimer’s Disease Using Plasma, MRI and Clinical Variables. May 31, 2024. doi:10.1101/2024.05.31.24308264

[101] Zhao Y, Wu P, Wu J, et al. Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning. Eur J Nucl Med Mol Imaging. 2022; 49(8): 2798-2811.

[102] Wu Y, Jiang JH, Chen L, et al. Use of radiomic features and support vector machine to distinguish Parkinson’s disease cases from normal controls. Ann Transl Med. 2019; 7(23): 773-773.

[103] Nakajima K, Saito S, Chen Z, et al. Diagnosis of Parkinson syndrome and Lewy-body disease using 123I-ioflupane images and a model with image features based on machine learning. Ann Nucl Med. 2022; 36(8): 765-776.

[104] Shao W, Leung KH, Xu J, Coughlin JM, Pomper MG, Du Y. Generation of digital brain phantom for machine learning application of dopamine transporter radionuclide imaging. Diagnostics. 2022; 12(8): 1945.

[105] Luo Y, Chen H, Gui M. Radiomics and hybrid models based on machine learning to predict levodopa-induced Dyskinesia of Parkinson’s disease in the first 6 years of levodopa treatment. Diagnostics. 2023; 13(15): 2511.

[106] Sun M, Jung W, Koltermann K, et al. Parkinson’s disease action tremor detection with supervised-leaning models. In: Proceedings of the 8th ACM/IEEE International Conference on Connected Health: Applications, Systems and Engineering Technologies. CHASE ’23. Association for Computing Machinery; 2024: 1-10.

[107] Quattrone A, Sarica A, Buonocore J, et al. Differentiating between common PSP phenotypes using structural MRI: a machine learning study. J Neurol. 2023; 270(11): 5502-5515.

[108] Haliasos N, Giakoumettis D, Gnanaratnasingham P, et al. Personalizing deep brain stimulation therapy for Parkinson’s disease with whole-brain MRI radiomics and machine learning. Cureus. 2024; 16(5): e5991.

[109] Shi Y, Mao H, Gao Q, et al. Potential of brain age in identifying early cognitive impairment in subcortical small-vessel disease patients. Front Aging Neurosci. 2022; 14: 973054.

[110] Mellema CJ, Montillo AA. Novel machine learning approaches for improving the reproducibility and reliability of functional and effective connectivity from functional MRI. J Neural Eng. 2022; 20(6): 066023-066023.

[111] Boutet A, Madhavan R, Elias GJB, et al. Predicting optimal deep brain stimulation parameters for Parkinson’s disease using functional MRI and machine learning. Nat Commun. 2021; 12(1): 3043.

[112] Ding K, Zhou M, Wang Z, et al. Graph Convolutional Networks for Multi-Modality Medical Imaging: Methods, Architectures, and Clinical Applications. April 20, 2022. doi:10.48550/arXiv.2202.08916

[113] Barrett MJ, Negida A, Mukhopadhyay N, et al. Optimizing screening for intrastriatal interventions in Huntington’s disease using predictive models. Mov Disord. 2024; 39(5): 855-862.

[114] Kohli M, Pustina D, Warner JH, et al. Predicting Huntington’s Disease State with Ensemble Learning & sMRI: More Than Just the Striatum. July 27, 2023.

[115] Haase R, Lehnen NC, Schmeel FC, et al. External evaluation of a deep learning-based approach for automated brain volumetry in patients with Huntington’s disease. Sci Rep. 2024; 14(1): 9243.

[116] Mohan A, Sun Z, Ghosh S, et al. A machine-learning derived Huntington’s disease progression model: insights for clinical trial design. Mov Disord. 2022; 37(3): 553-562.

[117] Ghofrani-Jahromi M, Poudel GR, Razi A, et al. Prognostic enrichment for early-stage Huntington’s disease: an explainable machine learning approach for clinical trial. NeuroImage Clin. 2024; 43: 103650.

[118] Simmons DA, Mills BD, Butler III RR, et al. Neuroimaging, urinary, and plasma biomarkers of treatment response in Huntington’s disease: preclinical evidence with the p75NTR ligand LM11A-31. Neurotherapeutics. 2021; 18(2): 1039-1063.

[119] Chiu PY, Hou PN, Hung GU, Hsieh TC, Chan PK, Kao CH. Real-world testing of a machine learning-derived visual scale for Tc99m TRODAT-1 for diagnosing lewy body disease: comparison with a traditional approach using semiquantification. J Pers Med. 2022; 12(9): 1369.

[120] Chen Q, Lowe VJ, Boeve BF, et al. β-Amyloid PET and 123I-FP-CIT SPECT in mild cognitive impairment at risk for Lewy body dementia. Neurology. 2021; 96(8): e1180-e1189.

[121] Yoo HS, Jeong SH, Oh KT, et al. Interrelation of striatal dopamine, brain metabolism and cognition in dementia with Lewy bodies. Brain. 2022; 145(12): 4448-4458.

[122] De Francesco S, Crema C, Archetti D, et al. Differential diagnosis of neurodegenerative dementias with the explainable MRI based machine learning algorithm MUQUBIA. Sci Rep. 2023; 13(1): 17355.

[123] Minne P, Fernandez-Quilez A, Aarsland D, et al. A study on 3D classical versus GAN-based augmentation for MRI brain image to predict the diagnosis of dementia with Lewy bodies and Alzheimer’s disease in a European multi-center study. Medical Imaging 2022: Computer-Aided Diagnosis. SPIE; 2022: 638-646.

[124] Redolfi A, De Francesco S, Crema C, et al. Differential diagnosis of neurodegenerative diseases using an innovative deep learning approach. Alzheimers Dement. 2023; 19(S2):e063043.

[125] Ganjizadeh A, Wei Y, Erickson BJ. From pixels to prognosis: AI-driven insights into neurodegenerative diseases. Med Res Arch. 2024; 12(6).

[126] McCombe N, Joshi A, Finn DP, et al. Distinguishing Lewy body dementia from Alzheimer’s disease using machine learning on heterogeneous data: a feasibility study. In: 2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). 2022: 4929-4933.

[127] Suzuki Y, Suzuki M, Shigenobu K, et al. A prospective multicenter validation study of a machine learning algorithm classifier on quantitative electroencephalogram for differentiating between dementia with Lewy bodies and Alzheimer’s dementia. PLoS One. 2022; 17(3): e0265484.

[128] Burgos N, Colliot O. Machine learning for classification and prediction of brain diseases: recent advances and upcoming challenges. Curr Opin Neurol. 2020; 33(4): 439.

[129] Yang J, Cai H, Liu N, et al. Application of radiomics in ischemic stroke. J Int Med Res. 2024; 52(4): 03000605241238141.

[130] Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med. 2014; 2(8): 80.

[131] Weaver NA, Kuijf HJ, Aben HP, et al. Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts. Lancet Neurol. 2021; 20(6): 448-459.

[132] Wiesen D, Sperber C, Yourganov G, Rorden C, Karnath HO. Using machine learning-based lesion behavior mapping to identify anatomical networks of cognitive dysfunction: spatial neglect and attention. NeuroImage. 2019; 201: 116000.

[133] Bonkhoff AK, Lim JS, Bae HJ, et al. Generative lesion pattern decomposition of cognitive impairment after stroke. Brain Commun. 2021; 3(2): fcab110.

[134] van Grinsven EE, Smits AR, van Kessel E, et al. The impact of etiology in lesion-symptom mapping—a direct comparison between tumor and stroke. NeuroImage Clin. 2023; 37: 103305.

[135] Salvalaggio A, De Filippo De Grazia M, Zorzi M, Thiebaut de Schotten M, Corbetta M. Post-stroke deficit prediction from lesion and indirect structural and functional disconnection. Brain. 2020; 143(7): 2173-2188.

[136] Shi L, Zhao L, Yeung FK, et al. Mapping the contribution and strategic distribution patterns of neuroimaging features of small vessel disease in poststroke cognitive impairment. J Neurol Neurosurg Amp Psychiatry. 2018; 89(9): 918.

[137] Arbula S, Ambrosini E, Della Puppa A, et al. Focal left prefrontal lesions and cognitive impairment: a multivariate lesion-symptom mapping approach. Neuropsychologia. 2020; 136: 107253.

[138] Chauhan S, Vig L, De Filippo De Grazia M, Corbetta M, Ahmad S, Zorzi M. A comparison of shallow and deep learning methods for predicting cognitive performance of stroke patients from MRI lesion images. Front Neuroinform. 2019; 13: 53.

[139] Karakis R, Gurkahraman K, Mitsis GD, Boudrias MH. Deep learning prediction of motor performance in stroke individuals using neuroimaging data. J Biomed Inform. 2023; 141: 104357.

[140] Jeong S, Lee EJ, Kim YH, et al. Deep learning approach using diffusion-weighted imaging to estimate the severity of aphasia in stroke patients. J Stroke. 2022; 24(1): 108-117.

[141] Dacosta-Aguayo R, Stephan-Otto C, Auer T, et al. Predicting cognitive recovery of stroke patients from the structural MRI connectome using a naïve Bayesian tree classifier. In: 2017 IEEE 30th International Symposium on Computer-Based Medical Systems (CBMS). 2017: 413-418.

[142] Lai S, Billot A, Varkanitsa M, et al. An exploration of machine learning methods for predicting post-stroke aphasia recovery. In: Proceedings of the 14th PErvasive Technologies Related to Assistive Environments Conference. PETRA ’21. Association for Computing Machinery; 2021: 556-564.

[143] Bassett DS, Sporns O. Network neuroscience. Nat Neurosci. 2017; 20(3): 353-364.

[144] Jia W, Zhou Y, Zuo L, Liu T, Li Z. Effects of brain atrophy and altered functional connectivity on poststroke cognitive impairment. Brain Res. 2024; 1822: 148635.

[145] Wang Y, Lu P, Zhan Y, et al. The contribution of white matter diffusion and cortical perfusion pathology to vascular cognitive impairment: a multimode imaging-based machine learning study. Front Aging Neurosci. 2021; 13: 687001.

[146] Haller S, Missonnier P, Herrmann FR, et al. Individual classification of mild cognitive impairment subtypes by support vector machine analysis of white matter DTI. Am J Neuroradiol. 2012; 34(2): 283-291.

[147] Peng Y, Zheng Y, Yuan Z, et al. The characteristics of brain network in patient with post-stroke depression under cognitive task condition. Front Neurosci. 2023; 17: 1242543.

[148] Hussain I, Park SJ. Quantitative evaluation of task-induced neurological outcome after stroke. Brain Sci. 2021; 11(7): 900.

[149] Lee M, Hong Y, An S, et al. Machine learning-based prediction of post-stroke cognitive status using electroencephalography-derived brain network attributes. Front Aging Neurosci. 2023; 15: 1238274.

[150] Wei Z, Li M, Fan H. Hybrid Deep Learning Model for the Risk Prediction of Cognitive Impairment in Stroke Patients. 2022. doi:10.21203/rs.3.rs-2318006/v1

[151] Ji W, Wang C, Chen H, Liang Y, Wang S. Predicting post-stroke cognitive impairment using machine learning: a prospective cohort study. J Stroke Cerebrovasc Dis. 2023; 32(11): 107354.

[152] Fast L, Temuulen U, Villringer K, et al. Machine learning-based prediction of clinical outcomes after first-ever ischemic stroke. Front Neurol. 2023; 14: 1114360.

[153] Al-Mekhlafi ZG, Senan EM, Rassem TH, et al. Deep learning and machine learning for early detection of stroke and haemorrhage. Comput Mater Contin. 2022; 72(1): 775-796.

[154] Meng Y, Wang H, Wu C, Liu X, Qu L, Shi Y. Prediction model of hemorrhage transformation in patient with acute ischemic stroke based on multiparametric MRI radiomics and machine learning. Brain Sci. 2022; 12(7): 858.

[155] Hall AN, Weaver B, Liotta E, et al. Identifying modifiable predictors of patient outcomes after intracerebral hemorrhage with machine learning. Neurocrit Care. 2021; 34(1): 73-84.

[156] Gu Y, Wang F, Gong L, Fang M, Liu X. A nomogram incorporating red blood cell indices to predict post-stroke cognitive impairment in the intracerebral hemorrhage population. Front Aging Neurosci. 2022; 14: 985386.

[157] Phuah CL, Chen Y, Strain JF, et al. Association of data-driven white matter hyperintensity spatial signatures with distinct cerebral small vessel disease etiologies. Neurology. 2022; 99(23): e2535-e2547.

[158] Tompkins G, Levman J, Ijner P, Shiohama T, Takahashi E. Cortical thickness in clinical moyamoya disease: a magnetic resonance imaging study. Int J Dev Neurosci. 2021; 81(8): 698-705.

[159] Akiyama Y, Mikami T, Mikuni N. Deep learning-based approach for the diagnosis of moyamoya disease. J Stroke Cerebrovasc Dis. 2020; 29(12): 105322.

[160] Shen XX, Zhang HD, Fu HG, et al. Association of cognitive function and hypoperfusion in Moyamoya disease patients without stroke. J Cereb Blood Flow Metab. Published online November 17, 2022: 0271678X2211403. doi:10.1177/0271678x221140349

[161] Gao M, Lam CLM, Lui WM, Lau KK, Lee TMC. Preoperative brain connectome predicts postoperative changes in processing speed in moyamoya disease. Brain Commun. 2022; 4(5): fcac213.

[162] Chen X, Zeng W, Wu G. Identification of vascular cognitive impairment in adult moyamoya disease via integrated graph convolutional network. In: Wang L, Dou Q, Fletcher PT, Speidel S, Li S, eds. Medical Image Computing and Computer Assisted Intervention—MICCAI 2022. Springer Nature Switzerland; 2022: 669-678.

[163] Lei Y, Chen X, Su JB, et al. Recognition of cognitive impairment in adult moyamoya disease: a classifier based on high-order resting-state functional connectivity network. Front Neural Circuits. 2020; 14: 603208.

[164] Weng R, Ren S, Su J, et al. 18F-FDG PET and a classifier algorithm reveal a characteristic glucose metabolic pattern in adult patients with moyamoya disease and vascular cognitive impairment. Brain Imaging Behav. 2023; 17(2): 185-199.

[165] Balki I, Amirabadi A, Levman J, et al. Sample-size determination methodologies for machine learning in medical imaging research: a systematic review. Can Assoc Radiol J. 2019; 70(4): 344-353.

[166] Baum EB, Haussler D. What size net gives valid generalization? Neural Comput. 1989; 1(1): 151-160.

[167] Sohn CK, Bisdas S. Diagnostic accuracy of machine learning-based radiomics in grading gliomas: systematic review and meta-analysis. Contrast Media Mol Imaging. 2020; 2020: 1-12.

[168] Wagner MW, Namdar K, Biswas A, Monah S, Khalvati F, Ertl-Wagner BB. Radiomics, machine learning, and artificial intelligence—what the neuroradiologist needs to know. Neuroradiology. 2021; 63(12): 1957-1967.

[169] Giger ML. Computer-aided detection and diagnosis/radiomics/machine learning/deep learning in medical imaging. Med Phys. 2023; 50(S1): 50-53.

[170] Gupta R, Bilgin C, Jabal MS, et al. Quality assessment of radiomics studies on functional outcomes after acute ischemic stroke—a systematic review. World Neurosurg. 2024; 183: 164-171.

[171] Scicolone R, Vacca S, Pisu F, et al. Radiomics and artificial intelligence: general notions and applications in the carotid vulnerable plaque. Eur J Radiol. 2024; 176: 111497.

[172] Betrouni N, Jiang J, Duering M, et al. Texture features of magnetic resonance images predict poststroke cognitive impairment: validation in a multicenter study. Stroke. 2022; 53(11): 3446-3454.

[173] Liao D, Zhang ZQ, Guo ZP, et al. Disrupted topological organization of functional brain networks is associated with cognitive impairment in hypertension patients: a resting-state fMRI study. Neuroradiology. 2023. doi:10.1007/s00234-022-03061-1

[174] Maksum Y, Amirli A, Amangeldi A, et al. Computational acceleration of topology optimization using parallel computing and machine learning methods—analysis of research trends. J Ind Inf Integr. 2022; 28: 100352.

[175] Bian J, Wang X, Hao W, Zhang G, Wang Y. The differential diagnosis value of radiomics-based machine learning in Parkinson’s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2023; 15: 1199826.

[176] Gong L, Gu Y, Yu Q, et al. Prognostic factors for cognitive recovery beyond early poststroke cognitive impairment (PSCI): a prospective cohort study of spontaneous intracerebral hemorrhage. Front Neurol. 2020; 11: 278.

[177] Kosgallana A, Cordato D, Chan DKY, Yong J. Use of cognitive screening tools to detect cognitive impairment after an ischaemic stroke: a systematic review. SN Compr Clin Med. 2019; 1(4): 255-262.

[178] Zhu Y, Zhao Y, Lu Y, et al. The association between plasma soluble triggering receptor expressed on myeloid cells 2 and cognitive impairment after acute ischemic stroke. J Affect Disord. 2022; 299: 287-293.

[179] Jeffares I, Rohde D, Doyle F, Horgan F, Hickey A. The impact of stroke, cognitive function and post-stroke cognitive impairment (PSCI) on healthcare utilisation in Ireland: a cross-sectional nationally representative study. BMC Health Serv Res. 2022; 22(1): 414.

[180] Lee M, Yeo NY, Ahn HJ, et al. Prediction of post-stroke cognitive impairment after acute ischemic stroke using machine learning. Alzheimers Res Ther. 2023; 15(1): 147.

[181] Zhong X, Li J, Lv S, et al. Development and Validation of a Machine Learning-Based Risk Prediction Model for Post-Stroke Cognitive Impairment. 2024.

[182] Salvadori E, Cova I, Mele F, Pomati S, Pantoni L. Prediction of post-stroke cognitive impairment by Montreal Cognitive Assessment (MoCA) performances in acute stroke: comparison of three normative datasets. Aging Clin Exp Res. 2022; 34(8): 1855-1863.

[183] Esmael A, Elsherief M, Eltoukhy K. Prevalence of cognitive impairment in acute ischaemic stroke and use of Alberta Stroke Programme Early CT Score (ASPECTS) for early prediction of post-stroke cognitive impairment. Neurol Neurochir Pol. 2021; 55(2): 179-185.

[184] Tveiten A, Ljøstad U, Mygland Å, Naess H. Functioning of long-term survivors of first-ever intracerebral hemorrhage. Acta Neurol Scand. 2013; 129(4): 269-275.

[185] Suda S, Muraga K, Ishiwata A, et al. Early cognitive assessment following acute stroke: feasibility and comparison between Mini-Mental State Examination and Montreal cognitive assessment. J Stroke Cerebrovasc Dis. 2020; 29(4): 104688.

[186] Li L, Wei M, Liu B, et al. Deep learning for hemorrhagic lesion detection and segmentation on brain CT images. IEEE J Biomed Health Inform. 2021; 25(5): 1646-1659.

[187] El Husseini N, Katzan IL, Rost NS, et al. Cognitive impairment after ischemic and hemorrhagic stroke: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2023; 54(6): e272-e291.

[188] Runchey S, McGee S. Does this patient have a hemorrhagic stroke? Clinical findings distinguishing hemorrhagic stroke from ischemic stroke. JAMA. 2010; 303(22): 2280-2286.

[189] Kocak B. Key concepts, common pitfalls, and best practices in artificial intelligence and machine learning: focus on radiomics. Diagn Interv Radiol. 2022; 28(5): 450-462.

[190] Lee R, Choi H, Park KY, Kim JM, Seok JW. Prediction of post-stroke cognitive impairment using brain FDG PET: deep learning-based approach. Eur J Nucl Med Mol Imaging. 2022; 49(4): 1254-1262.

[191] Hatt M, Parmar C, Qi J, El Naqa I. Machine (deep) learning methods for image processing and radiomics. IEEE Trans Radiat Plasma Med Sci. 2019; 3(2): 104-108.

[192] Severn C, Suresh K, Görg C, Choi YS, Jain R, Ghosh D. A pipeline for the implementation and visualization of explainable machine learning for medical imaging using radiomics features. Sensors. 2022; 22(14): 5205.

[193] Song J, Yin Y, Wang H, Chang Z, Liu Z, Cui L. A review of original articles published in the emerging field of radiomics. Eur J Radiol. 2020; 127: 108991.

[194] Carré A, Klausner G, Edjlali M, et al. Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics. Sci Rep. 2020; 10(1): 12340.

[195] Ding H, Wu C, Liao N, et al. Radiomics in oncology: a 10-year bibliometric analysis. Front Oncol. 2021; 11: 689802.

[196] Papadimitroulas P, Brocki L, Christopher Chung N, et al. Artificial intelligence: deep learning in oncological radiomics and challenges of interpretability and data harmonization. Phys Med. 2021; 83: 108-121.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.